COMBINED USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND HEMATOPOIETIC GROWTH FACTORS FOR TREATING HEMATOPOIETIC DISEASES

摘要

The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of aplasia after chemotherapy.